Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
about
Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damageInteraction between the N-terminal domain of human DNA topoisomerase I and the arginine-serine domain of its substrate determines phosphorylation of SF2/ASF splicing factorCell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosisActive heterodimers are formed from human DNA topoisomerase II alpha and II beta isoformshMre11 and hRad50 nuclear foci are induced during the normal cellular response to DNA double-strand breaksThe interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53Evolving concepts in cancer therapy through targeting sphingolipid metabolismVoreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase IICharacterization of cDNA encoding the mouse DNA topoisomerase II that can complement the budding yeast top2 mutationDNA topoisomerase II distribution in mouse preimplantation embryosExon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intronRapid exchange of mammalian topoisomerase II alpha at kinetochores and chromosome arms in mitosisCasein kinase II catalyzes a mitotic phosphorylation on threonine 1342 of human DNA topoisomerase IIalpha, which is recognized by the 3F3/2 phosphoepitope antibody.Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signalingReversing chromatin accessibility differences that distinguish homologous mitotic metaphase chromosomes.Simultaneous measurement of cell cycle phase position and ionizing radiation-induced DNA strand breakage in single human tumour cells using laser scanning confocal imaging.Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.Interaction between tumor suppressor adenomatous polyposis coli and topoisomerase IIalpha: implication for the G2/M transition.DNA topoisomerase II-dependent control of the cell cycle progression in root meristems of Allium cepa.Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancerDNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?Analysis of human antitopoisomerase-I idiotypesGenetic analysis of the gyrase A-like domain of DNA topoisomerase II of Saccharomyces cerevisiaeUltrasensitive isolation, identification and quantification of DNA-protein adducts by ELISA-based RADAR assayKinetics of chromosome condensation in the presence of topoisomerases: a phantom chain model.The dynamics of DNA topoisomerase IIalpha in living cellsEarly G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations.Condensin II initiates sister chromatid resolution during S phase.Depletion of topoisomerase IIalpha leads to shortening of the metaphase interkinetochore distance and abnormal persistence of PICH-coated anaphase threads.Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks.Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.Emerging DNA topisomerase inhibitors as anticancer drugs.Immunohistochemical study of DNA topoisomerase II in human gastric disordersEukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats.Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function.Decondensing the protamine domain for transcriptionMitotic chromatin condensation in vitro using somatic cell extracts and nuclei with variable levels of endogenous topoisomerase II.Topoisomerase II alpha is associated with the mammalian centromere in a cell cycle- and species-specific manner and is required for proper centromere/kinetochore structure.Developmental regulation of Drosophila DNA topoisomerase II
P2860
Q24317273-5C7C9A59-90B1-432D-985E-B813064093F0Q24548056-FBB03485-7031-4B29-80AD-543C203B5165Q24603316-7850BBA6-4141-406B-A5A5-26BB0A39AF4FQ24629778-AAEA34E9-E087-4503-9281-157146AC93CFQ24644470-D475EA3D-0A5D-4052-8F02-DD8B1FB91C40Q24679341-463F3438-E963-4A21-AB55-6D12588314BEQ26863646-EBF44E69-E2E4-4145-AD1B-C0E84ED09967Q28473683-3BCB171B-F573-46D5-8949-FD04BDB37B1BQ28507775-E3849337-AC22-4CBB-8A5F-A8AB5412044AQ28586945-AFD6FECD-D075-42BD-9559-91583F759AEBQ28749651-38DE9B09-5528-42DE-83D3-EF9AAEB3D77DQ30441918-75C74072-DCA3-4A94-8628-CDD962FDD63FQ30472783-A969BB13-81F1-4401-AB8C-3ED1F5790883Q30496293-D7C6D1EA-5B0D-476B-9880-EFADCF50C32DQ30660924-1C6ADD21-7B50-4ADF-A1F9-A6A7282756CCQ30812537-48B25425-E8EA-470E-9C90-48DC01E2C864Q31911584-29EAEA5A-BB38-4AD8-8B1C-B1BAB770DB88Q33207433-8F73B551-CA23-4496-A047-87F74F4BE1D0Q33352443-BBB9A041-B64B-4584-A866-50ADE0DFEEDFQ33357244-F4056415-19E6-4970-AE80-489D01DDEEF0Q33366785-01CB4B7A-6624-4040-8E4F-EF677B6C913CQ33734562-1FDBA100-0553-48A3-A7DF-5B991D426447Q33901961-1BE7ADB7-A9C8-4EDC-AA6F-857D4297F9D1Q33958149-4174CA4B-2114-4A97-9038-E0F7DB5C58E8Q33983494-B0F302D6-47F8-4373-9B15-4DB5488CC827Q34115032-95A38AFB-4726-444C-A022-FBC7945D72CBQ34175350-3BB51857-EE37-4C7D-A9A7-0C076112756FQ34210998-B04F5CAA-0F62-486F-B94E-8FAC9BC94984Q34327315-3E75CABA-B5AD-432F-8F93-94F5792D31CFQ34706012-9508D499-5601-4DE2-BA65-9DF0A28ED76AQ35640121-1B8A75BC-F3F0-4F32-95EA-38B51CD6BBA4Q35763155-7A86CDB1-3AEB-4930-8F40-44CB7B36CDCEQ35779294-9DB482FD-886E-451D-9B25-161739D99B49Q35782052-BBFFFF7E-75CA-4A68-82F4-C0EC9F8AB245Q35825156-B0E7B744-D107-43C9-A803-AC7CFFC8D698Q35833642-03CA833F-EC12-4222-B547-4BC871B0AF4AQ35850153-AAF87B81-8748-41B5-A4B9-C08283EE00C8Q36224150-63138C61-6D2E-4EF0-B15C-77923DAD36DBQ36237342-BDC3293C-624D-44E8-AC77-2CFA7E231F0EQ36529104-32109E2C-6226-4E5B-9A11-5B66EA850185
P2860
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
description
1988 nî lūn-bûn
@nan
1988 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
@ast
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
@en
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
@nl
type
label
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
@ast
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
@en
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
@nl
prefLabel
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
@ast
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
@en
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
@nl
P2093
P2860
P356
P1476
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
@en
P2093
W C Earnshaw
W N Hittelman
P2860
P304
P356
10.1073/PNAS.85.4.1086
P407
P577
1988-02-01T00:00:00Z